Smoking is associated with reduced serum levels of the antioxidant enzyme, paraoxonase, in Type 2 diabetic patients
- PMID: 15089785
- DOI: 10.1111/j.1464-5491.2004.01163.x
Smoking is associated with reduced serum levels of the antioxidant enzyme, paraoxonase, in Type 2 diabetic patients
Abstract
Aims: To analyse the association of smoking with paraoxonase (PON1) in Type 2 diabetic patients.
Methods: Type 2 diabetic patients were recruited independently in two centres (Ancona, Italy and Geneva, Switzerland) and serum PON1 mass and activities were assayed. Current smoking status was established and its association with serum PON1 analysed.
Results: Type 2 diabetic patients who smoked had significantly lower serum PON1 mass and activity. This was evident in both groups of patients, even though Swiss patients were composed of coronary patients. Multivariate analyses established that smoking was an independent determinant of serum PON1 status.
Conclusions: Smoking is associated with reduced serum levels of the antioxidant enzyme, PON1, even against an already unfavourable background of diabetes and coronary disease. It suggests that a combination of smoking and diabetes may be particularly deleterious for PON1 and consequently for the anti-oxidant capacity of high-density lipoproteins.
Similar articles
-
Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients.Nutr Metab Cardiovasc Dis. 2009 Nov;19(9):613-9. doi: 10.1016/j.numecd.2008.12.005. Epub 2009 Feb 6. Nutr Metab Cardiovasc Dis. 2009. PMID: 19201174
-
High-density lipoprotein composition and paraoxonase activity in Type I diabetes.Clin Sci (Lond). 2001 Dec;101(6):659-70. Clin Sci (Lond). 2001. PMID: 11724654
-
Postprandial modulation of serum paraoxonase activity and concentration in diabetic and non-diabetic subjects.Nutr Metab Cardiovasc Dis. 2006 Oct;16(7):457-65. doi: 10.1016/j.numecd.2005.09.005. Epub 2006 Jan 18. Nutr Metab Cardiovasc Dis. 2006. PMID: 17015182
-
Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1.Clin Sci (Lond). 2004 Nov;107(5):435-47. doi: 10.1042/CS20040187. Clin Sci (Lond). 2004. PMID: 15265000 Review.
-
Importance of paraoxonase 1 (PON1) as an antioxidant and antiatherogenic enzyme in the cardiovascular complications of type 2 diabetes: Genotypic and phenotypic evaluation.Diabetes Res Clin Pract. 2020 Mar;161:108067. doi: 10.1016/j.diabres.2020.108067. Epub 2020 Feb 7. Diabetes Res Clin Pract. 2020. PMID: 32044348 Review.
Cited by
-
Changes in arachidonic acid (AA)- and linoleic acid (LA)-derived hydroxy metabolites and their interplay with inflammatory biomarkers in response to drastic changes in air pollution exposure.Environ Res. 2021 Sep;200:111401. doi: 10.1016/j.envres.2021.111401. Epub 2021 Jun 2. Environ Res. 2021. PMID: 34089746 Free PMC article.
-
Paraoxonase (PON)1 Q192R functional genotypes and PON1 Q192R genotype by smoking interactions are risk factors for the metabolic syndrome, but not overweight or obesity.Redox Rep. 2014 Nov;19(6):232-41. doi: 10.1179/1351000214Y.0000000093. Epub 2014 Jul 18. Redox Rep. 2014. PMID: 25037113 Free PMC article.
-
Developmental and social deficits and enhanced sensitivity to prenatal chlorpyrifos in PON1-/- mouse pups and adults.PLoS One. 2020 Sep 25;15(9):e0239738. doi: 10.1371/journal.pone.0239738. eCollection 2020. PLoS One. 2020. PMID: 32976529 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous